big changes in treating chronic hepatitis C with two new oral antivirals, Olysio (simeprevir) and Sovaldi (sofosbuvir)

February 2014

You'll see big changes in treating chronic hepatitis C with two new oral antivirals, Olysio (simeprevir) and Sovaldi (sofosbuvir).

These new drugs...and others in the pipeline...will make it easier for primary care providers to treat hepatitis C. Eventually simpler oral regimens will replace interferon...and be better tolerated.

Olysio (oh-LI-see-oh) is a new oral PROTEASE inhibitor...and will be added to injectable interferon and oral ribavirin.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote